<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02210715</url>
  </required_header>
  <id_info>
    <org_study_id>switchMerck</org_study_id>
    <nct_id>NCT02210715</nct_id>
  </id_info>
  <brief_title>Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients</brief_title>
  <official_title>Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People infected with HIV are living longer thanks to the use of antiretroviral therapy&#xD;
      (cART). In aging HIV persons, other factors are associated with early death. One of the major&#xD;
      factors is liver disease, which can be due to liver infections or reasons such as fatty&#xD;
      liver. Fatty liver in the general population is a serious problem, affecting 30% of Canadian&#xD;
      population. A specific type of fatty liver characterized by much inflammation, named&#xD;
      nonalcoholic steatohepatitis (NASH) can lead to cirrhosis and death. Persons living with HIV&#xD;
      can be at increased risk of NASH because of toxic effect of certain types of cART on the&#xD;
      liver, obesity and other metabolic factors (for example diabetes). Some scientific data&#xD;
      suggest that newer cART are associated with less fatty liver and liver damage. However, NASH&#xD;
      has not been studied in detail in persons living with HIV. One reason for the lack of&#xD;
      research is one of the only ways to detect liver disease is to undergo liver biopsy which can&#xD;
      be painful and has complications. Recently, a new non-invasive technology (Fibroscan) has&#xD;
      been developed which can tell doctors how much a liver is damaged and how much fat it&#xD;
      contains without pain or complications. Moreover, a simple test measuring a specific protein&#xD;
      in the blood, the cytokeratin 18 (CK-18), can help the diagnosis of NASH. We will study the&#xD;
      effect of switching cART to newer types of HIV medication in patients with a non-invasive&#xD;
      diagnosis of NASH done by Fibroscan and cytokeratin 18. We expect that switching older cART&#xD;
      to less hepatotoxic drugs will lead to improvement of liver damage, fatty liver and NASH&#xD;
      diagnosed by Fibroscan and cytokeratin 18. To evaluate this approach we plan to recruit 58&#xD;
      consenting HIV mono infected patients with non-invasive diagnosis of NASH and/or fatty liver&#xD;
      with liver damage. Participants will undergo Fibroscan, a blood test for cytokeratin 18, a&#xD;
      complete physical examination and laboratory tests every 3 months for 12 months, then at 18&#xD;
      and 24 months. The effect of the switching of HIV medications will be recorded. We anticipate&#xD;
      that the current study will provide evidence for reduction of inflammation and liver damage&#xD;
      with newer cART for treatment of HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current Non-invasive tools for liver fibrosis and fatty liver/NASH, including Fibroscan/CAP&#xD;
      and serum cytokeratin 18 (CK-18), are accurate and ideal for screening and monitoring. To&#xD;
      date, there has been no study using these accurate non-invasive tools to prospectively&#xD;
      evaluate the effect of switching cART to raltegravir in HIV mono-infected patients with&#xD;
      suppressed HIV RNA who have evidence of fatty liver and/or significant liver fibrosis in&#xD;
      order to determine whether such a strategy may slow fibrosis and steatosis progression rates.&#xD;
&#xD;
      Once a candidate for screening has been identified, study details will be carefully discussed&#xD;
      with the subject. The subject will be asked to read and sign the approved informed consent&#xD;
      form prior to any assessments being performed. Self-administered questionnaires will collect&#xD;
      information on Alcohol use and Disorders Identification Test (audit C), drug use. chart&#xD;
      review, (demographics, medication medical history).&#xD;
&#xD;
      Blood samples will be obtained for clinical laboratory evaluations (as per standard of care)&#xD;
      at baseline, and all follow-up visits, plus serum CK-18 that will be obtained at all&#xD;
      follow-up visits. Routine hematology and chemistry evaluations will include: complete blood&#xD;
      count (CBC) with differential, CD4 and CD8 cell counts, viral load, C-reactive Protein,&#xD;
      D-dimer, and measurements of hepatic, pancreatic and renal function, fasting insulin,&#xD;
      creatine kinase, glucose and lipid profiles. Plasma HIV RNA levels will be measured with a&#xD;
      lower limit of detection of 50 copies/mL. Clinical laboratory evaluations for hematology,&#xD;
      biochemistry, CD4/CD8, viral load and serology will be performed at the chest institute as&#xD;
      per local practices. Fibroscan will be performed on a fasting patient. The probe transducer&#xD;
      will be placed on the skin, between the rib bones at the level of the right lobe of the&#xD;
      liver. An experienced operator (&gt; 500 examinations before the study), will perform the&#xD;
      Fibroscan and the software will calculate the median . The standard M probe will be used in&#xD;
      all patients. The XL probe will be used in obese patients (BMI&gt;30 Kg/m2) or if the M probe&#xD;
      fails to provide accurate results. CAP examination will be performed at the same time to&#xD;
      diagnose fatty liver. A valid Fibroscan result will be defined by 10 validated measures and&#xD;
      IQR &lt; 30% of the median. The following cut-off values will be applied to diagnose fibrosis by&#xD;
      Fibroscan: 1) 8 kilopascal (kPa) for significant liver fibrosis; 2) 13 kPa for cirrhosis.&#xD;
      Fatty liver by CAP will be diagnosed with the following cut-off values: 1) 237.8 dB/m for&#xD;
      mild steatosis; 2) 260 dB/m for moderate steatosis; 3) 292.3 dB/m for severe steatosis.&#xD;
&#xD;
      Subject Identification (ID) numbers will be assigned sequentially to each subject who is&#xD;
      eligible to participate in the study. The Subject ID Number will consist of a three digit&#xD;
      centre number and a three digit number according to chronological order of entry. If a&#xD;
      patient discontinues from the study the Subject ID Number will not be reused. The Subject ID&#xD;
      Numbers will be used for identification of subjects in the source documentation, and&#xD;
      laboratory samples. This will ensure that subject data and laboratory samples leaving the&#xD;
      study sites will be identified and tracked.&#xD;
&#xD;
      Randomization to study groups will be done using a computer-generated random allocation with&#xD;
      stratification by gender. Summary statistics (mean, median, standard deviation, interquartile&#xD;
      range) will be obtained for clinical and demographic data collected between baseline and&#xD;
      study conclusion. The fatty liver and liver fibrosis scores by CAP and Fibroscan,&#xD;
      respectively, at month 24 will be expressed as a function of exposure group, adjusting for&#xD;
      baseline values of each outcome using an analysis of covariance (ANCOVA) model. The average&#xD;
      difference in change of steatosis and fibrosis scores between the two groups and associated&#xD;
      hypothesis tests will be obtained from the ANCOVA model. All analyses will be based on an&#xD;
      intention-to-treat basis, that is, patients' data will be analyzed as randomized. To assess&#xD;
      the sensitivity of inferences to missing data, we will generate plausible values for missing&#xD;
      observations using multiple imputations (MI), which is a relatively objective methodology for&#xD;
      handling missing data in longitudinal studies. In MI, multiple plausible values are generated&#xD;
      for each missing item from the joint distribution of observed data using a Bayesian&#xD;
      framework, and the results are pooled using established rules while simultaneously accounting&#xD;
      for uncertainty in the imputation process. Multivariate logistic regression analysis will be&#xD;
      used to explore factors associated with non-invasive diagnosis of fatty liver/NASH and&#xD;
      significant liver fibrosis, including patient-related (age, gender, BMI), drug-induced (time&#xD;
      on and type of cART), metabolic (diabetes, insulin resistance, lipid profile, hypertension),&#xD;
      HIV-related (HIV viral load, CD4/CD8). Pearson correlation coefficient will be used to&#xD;
      measure the association between CK-18 and Fibroscan/CAP values, BMI, transaminases. All&#xD;
      hypotheses tests will be conducted at 5% level of significance (2-sided). Analyses will be&#xD;
      performed using R program for Windows Release 2.13.1.&#xD;
&#xD;
      The trial will be monitored for safety and efficacy by a Data Safety Monitoring Board (DSMB)&#xD;
      composed of clinicians, statisticians/methodologists and a lay member appointed by the McGill&#xD;
      University Health center.&#xD;
&#xD;
      Adverse events (AEs) are defined as any untoward medical occurrence in a subject which does&#xD;
      not necessarily have a causal relationship with the study medication/intervention. An AE can&#xD;
      therefore be any unfavourable and unintended sign (including abnormal laboratory finding),&#xD;
      symptom, or disease temporally associated with the use of study drug/intervention, whether or&#xD;
      not it is related to the medication/intervention.&#xD;
&#xD;
      Stable chronic conditions which are present prior to clinical study entry and do not worsen&#xD;
      are not considered adverse events and will be accounted for in the subject's medical history.&#xD;
&#xD;
      Subjects who have an adverse event should be followed and treated by the Investigator until&#xD;
      the abnormal parameter or symptom has resolved or stabilized. It is up to the clinician to&#xD;
      determine that the AE is either resolved or that is has reached a stable state, after which&#xD;
      no further follow-up is necessary. There should also be source documentation to support this&#xD;
      determination. At each contact with the subject, information regarding adverse events will be&#xD;
      elicited by appropriate questioning and examinations, and will be recorded immediately on a&#xD;
      source document (e.g., progress notes, laboratory reports, survey tools, and data collection&#xD;
      tools). The start date, stop date, severity of each reportable event, and the PI's judgment&#xD;
      of the AE's relationship to the study, medication/intervention will also be recorded.&#xD;
&#xD;
      Any AE that occurs between baseline and 30 days following Week 24 (or at the time of early&#xD;
      discontinuation of the subject from the study for any reason) is to be recorded in the source&#xD;
      documentation (patient will be called). Surveillance for AEs will end at 30 days following&#xD;
      Week 24. If an serious adverse event (SAE) is ongoing at the time a subject&#xD;
      discontinues/completes the trial the SAE will be followed until the Investigator agrees that&#xD;
      the event is satisfactorily resolved or that no further follow-up is required.&#xD;
&#xD;
      Virologic failure must be considered for any patient with plasma HIV RNA ≥50 c/mL at any time&#xD;
      following randomization. For the purposes of clinical management in this study, virologic&#xD;
      failure is defined as: Two consecutive plasma HIV RNA ≥50 c/mL within four weeks of the&#xD;
      initial suspected virologic failure. Cases of confirmed virologic failure will trigger&#xD;
      genotypic virologic resistance testing, including integrase resistance testing, when plasma&#xD;
      HIV RNA &gt;400c/mL. The virologic failure definition is intended for guidance and Investigators&#xD;
      should use their discretion as to the most appropriate clinical management of their patients.&#xD;
      Due to the risk of developing integrase resistance in the setting of replicating HIV, change&#xD;
      of antiretroviral therapy for subjects randomized to raltegravir is indicated for those with&#xD;
      confirmed virologic failure. The choice of antiretroviral therapy will be left to the&#xD;
      discretion of the treating physician.&#xD;
&#xD;
      The conduct of this study will conform to the International Conference for Harmonization and&#xD;
      Good Clinical Practice (ICH-GCP) regulations and guidelines and the current revision of the&#xD;
      Declaration of Helsinki A copy of the protocol (including protocol amendments), all versions&#xD;
      of the informed consents, other information to be completed by subjects such as&#xD;
      questionnaires, and any proposed advertising/ recruitment materials must be reviewed and&#xD;
      approved by the research ethics board (REB) of each participating centre prior to&#xD;
      implementation of the study. The investigator will be responsible for obtaining REB approval&#xD;
      of the annual Continuing Review throughout the duration of the study. The investigator will&#xD;
      notify the REB of violations from the protocol and SAEs.&#xD;
&#xD;
      All subjects will be given detailed oral and written information about the study. Consent&#xD;
      forms describing in detail the study medications/intervention(s), study procedures,&#xD;
      anticipated benefits and potential risks will be given to each participant and written&#xD;
      documentation of informed consent is required prior to starting the study. Subjects must&#xD;
      voluntarily sign and date an informed consent document that has been approved by the REB&#xD;
      prior to any procedures being done specifically for the trial. Each subject should have&#xD;
      sufficient opportunity to discuss the study and consider the information in the consent&#xD;
      process prior to agreeing to participate. Subjects may withdraw consent at any time during&#xD;
      the course of the trial. The informed consent will be signed and dated by the subject, the&#xD;
      person who conducted the informed consent discussion and the investigator. The original&#xD;
      signed informed consent form will be retained in the subject's study files and a copy will be&#xD;
      provided to the subject.&#xD;
&#xD;
      All subject related information including the case report forms (CRFs), laboratory samples,&#xD;
      evaluation forms, reports, etc. will be kept strictly confidential. All records will be kept&#xD;
      in a secure, locked location and only research staff will have access to the records.&#xD;
      Subjects will be identified only by means of a coded number specific to each subject, and a&#xD;
      subject letter code. All computerized databases will identify subjects by numeric codes only,&#xD;
      and will be password protected. Upon request, clinical information may be reviewed by or&#xD;
      released to study monitors, auditors, Canadian Institutes of Health Research or regulatory&#xD;
      agencies. The REB or other government organizations, as part of their duties to ensure that&#xD;
      research subjects are protected may discontinue the study at any time. Regulatory authorities&#xD;
      and the study Sponsor retain the authority to suspend additional enrollment for the entire&#xD;
      study as applicable.&#xD;
&#xD;
      Data and study documents at all sites will be stored securely for 25 years, after which they&#xD;
      will be destroyed in keeping with the privacy and confidentiality regulations and guidelines.&#xD;
&#xD;
      Appropriate medical and research records for this study and regulatory/ institutional&#xD;
      requirements must be maintained for the protection of confidentiality of study subjects. The&#xD;
      Principal Investigator is responsible for assuring that the data collected are complete,&#xD;
      accurate, and recorded in a timely manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of fatty liver or liver fibrosis</measure>
    <time_frame>24 months</time_frame>
    <description>Difference in Fibroscan/CAP measurement from baseline to 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in serum CK-18 levels</measure>
    <time_frame>24 months</time_frame>
    <description>Difference in serum CK-18 levels as surrogate diagnostic marker of NASH from baseline to 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in transaminases levels</measure>
    <time_frame>24 months</time_frame>
    <description>Difference in transaminases levels (AST and/or ALT) from baseline to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in metabolic markers</measure>
    <time_frame>24 months</time_frame>
    <description>Difference in metabolic markers (HOMA; cholesterol or triglycerides levels; BMI) from baseline to 24 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>HIV</condition>
  <condition>Fatty Liver</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>switch to Isentress</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 subjects will be prescribed Raltegravir at the standard dose of 400 mg p.o. b.i.d. for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continue usual antiretroviral therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isentress.</intervention_name>
    <description>28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.</description>
    <arm_group_label>switch to Isentress</arm_group_label>
    <other_name>Raltegravir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continue usual antiretroviral therapy</intervention_name>
    <description>28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.</description>
    <arm_group_label>Continue usual antiretroviral therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years or older&#xD;
&#xD;
          2. Confirmed positive serology for HIV mono-infection&#xD;
&#xD;
          3. Valid Fibroscan/CAP results&#xD;
&#xD;
          4. Able to provide informed consent (available in French or English)&#xD;
&#xD;
          5. Receiving any approved antiretroviral regimen that does not contain&#xD;
             integrase-inhibitor&#xD;
&#xD;
          6. Evidence of fatty liver (CAP&gt;237.8dB/m) AND/OR evidence of significant liver fibrosis&#xD;
             (Fibroscan &gt; 8KPa)&#xD;
&#xD;
          7. HIV viral suppression (&lt;50 copies/mL) for at least 6 months&#xD;
&#xD;
          8. No prior evidence of resistance to raltegravir or co-administered nucleoside backbone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical evidence of decompensated liver disease at entry (e.g. ascites, bleeding&#xD;
             esophageal varices, hepatic encephalopathy, or hepatoma/ hepatocellular carcinoma).&#xD;
&#xD;
          2. Co-infection with hepatitis C virus (HCV) or hepatitis C virus (HBV) (presence of&#xD;
             serum HCV-Ab or HBsAg);&#xD;
&#xD;
          3. Alpha-fetoprotein (AFP) greater than or equal to 200 ng/mL at screening.&#xD;
&#xD;
          4. Known or suspected Wilson's disease, alpha-1-antitrypsin deficiency, celiac disease or&#xD;
             other cause of chronic liver disease.&#xD;
&#xD;
          5. Chronic renal insufficiency (eGFR &lt; 20 mL/min) at screening.&#xD;
&#xD;
          6. Pregnancy and planned pregnancy (not using adequate contraception).&#xD;
&#xD;
          7. Women who are breastfeeding.&#xD;
&#xD;
          8. Active opportunistic infection (except oral thrush) or neoplasm (except Kaposi's&#xD;
             sarcoma, skin cancer, or cancer of the cervix or anus, unless known or suspected liver&#xD;
             metastasis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giada Sebastiani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Giada Sebastiani</investigator_full_name>
    <investigator_title>Dr Giada Sebastiani MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02210715
org study id: switchMerck
nct id: NCT02210715
lead sponsor: 
collaborator: 
has dmc: Yes
People infected with HIV are living longer thanks to the use of antiretroviral therapy
      (cART). In aging HIV persons, other factors are associated with early death. One of the major
      factors is liver disease, which can be due to liver infections or reasons such as fatty
      liver. Fatty liver in the general population is a serious problem, affecting 30% of Canadian
      population. A specific type of fatty liver characterized by much inflammation, named
      nonalcoholic steatohepatitis (NASH) can lead to cirrhosis and death. Persons living with HIV
      can be at increased risk of NASH because of toxic effect of certain types of cART on the
      liver, obesity and other metabolic factors (for example diabetes). Some scientific data
      suggest that newer cART are associated with less fatty liver and liver damage. However, NASH
      has not been studied in detail in persons living with HIV. One reason for the lack of
      research is one of the only ways to detect liver disease is to undergo liver biopsy which can
      be painful and has complications. Recently, a new non-invasive technology (Fibroscan) has
      been developed which can tell doctors how much a liver is damaged and how much fat it
      contains without pain or complications. Moreover, a simple test measuring a specific protein
      in the blood, the cytokeratin 18 (CK-18), can help the diagnosis of NASH. We will study the
      effect of switching cART to newer types of HIV medication in patients with a non-invasive
      diagnosis of NASH done by Fibroscan and cytokeratin 18. We expect that switching older cART
      to less hepatotoxic drugs will lead to improvement of liver damage, fatty liver and NASH
      diagnosed by Fibroscan and cytokeratin 18. To evaluate this approach we plan to recruit 58
      consenting HIV mono infected patients with non-invasive diagnosis of NASH and/or fatty liver
      with liver damage. Participants will undergo Fibroscan, a blood test for cytokeratin 18, a
      complete physical examination and laboratory tests every 3 months for 12 months, then at 18
      and 24 months. The effect of the switching of HIV medications will be recorded. We anticipate
      that the current study will provide evidence for reduction of inflammation and liver damage
      with newer cART for treatment of HIV infection.
Current Non-invasive tools for liver fibrosis and fatty liver/NASH, including Fibroscan/CAP
      and serum cytokeratin 18 (CK-18), are accurate and ideal for screening and monitoring. To
      date, there has been no study using these accurate non-invasive tools to prospectively
      evaluate the effect of switching cART to raltegravir in HIV mono-infected patients with
      suppressed HIV RNA who have evidence of fatty liver and/or significant liver fibrosis in
      order to determine whether such a strategy may slow fibrosis and steatosis progression rates.

      Once a candidate for screening has been identified, study details will be carefully discussed
      with the subject. The subject will be asked to read and sign the approved informed consent
      form prior to any assessments being performed. Self-administered questionnaires will collect
      information on Alcohol use and Disorders Identification Test (audit C), drug use. chart
      review, (demographics, medication medical history).

      Blood samples will be obtained for clinical laboratory evaluations (as per standard of care)
      at baseline, and all follow-up visits, plus serum CK-18 that will be obtained at all
      follow-up visits. Routine hematology and chemistry evaluations will include: complete blood
      count (CBC) with differential, CD4 and CD8 cell counts, viral load, C-reactive Protein,
      D-dimer, and measurements of hepatic, pancreatic and renal function, fasting insulin,
      creatine kinase, glucose and lipid profiles. Plasma HIV RNA levels will be measured with a
      lower limit of detection of 50 copies/mL. Clinical laboratory evaluations for hematology,
      biochemistry, CD4/CD8, viral load and serology will be performed at the chest institute as
      per local practices. Fibroscan will be performed on a fasting patient. The probe transducer
      will be placed on the skin, between the rib bones at the level of the right lobe of the
      liver. An experienced operator (> 500 examinations before the study), will perform the
      Fibroscan and the software will calculate the median . The standard M probe will be used in
      all patients. The XL probe will be used in obese patients (BMI>30 Kg/m2) or if the M probe
      fails to provide accurate results. CAP examination will be performed at the same time to
      diagnose fatty liver. A valid Fibroscan result will be defined by 10 validated measures and
      IQR < 30% of the median. The following cut-off values will be applied to diagnose fibrosis by
      Fibroscan: 1) 8 kilopascal (kPa) for significant liver fibrosis; 2) 13 kPa for cirrhosis.
      Fatty liver by CAP will be diagnosed with the following cut-off values: 1) 237.8 dB/m for
      mild steatosis; 2) 260 dB/m for moderate steatosis; 3) 292.3 dB/m for severe steatosis.

      Subject Identification (ID) numbers will be assigned sequentially to each subject who is
      eligible to participate in the study. The Subject ID Number will consist of a three digit
      centre number and a three digit number according to chronological order of entry. If a
      patient discontinues from the study the Subject ID Number will not be reused. The Subject ID
      Numbers will be used for identification of subjects in the source documentation, and
      laboratory samples. This will ensure that subject data and laboratory samples leaving the
      study sites will be identified and tracked.

      Randomization to study groups will be done using a computer-generated random allocation with
      stratification by gender. Summary statistics (mean, median, standard deviation, interquartile
      range) will be obtained for clinical and demographic data collected between baseline and
      study conclusion. The fatty liver and liver fibrosis scores by CAP and Fibroscan,
      respectively, at month 24 will be expressed as a function of exposure group, adjusting for
      baseline values of each outcome using an analysis of covariance (ANCOVA) model. The average
      difference in change of steatosis and fibrosis scores between the two groups and associated
      hypothesis tests will be obtained from the ANCOVA model. All analyses will be based on an
      intention-to-treat basis, that is, patients' data will be analyzed as randomized. To assess
      the sensitivity of inferences to missing data, we will generate plausible values for missing
      observations using multiple imputations (MI), which is a relatively objective methodology for
      handling missing data in longitudinal studies. In MI, multiple plausible values are generated
      for each missing item from the joint distribution of observed data using a Bayesian
      framework, and the results are pooled using established rules while simultaneously accounting
      for uncertainty in the imputation process. Multivariate logistic regression analysis will be
      used to explore factors associated with non-invasive diagnosis of fatty liver/NASH and
      significant liver fibrosis, including patient-related (age, gender, BMI), drug-induced (time
      on and type of cART), metabolic (diabetes, insulin resistance, lipid profile, hypertension),
      HIV-related (HIV viral load, CD4/CD8). Pearson correlation coefficient will be used to
      measure the association between CK-18 and Fibroscan/CAP values, BMI, transaminases. All
      hypotheses tests will be conducted at 5% level of significance (2-sided). Analyses will be
      performed using R program for Windows Release 2.13.1.

      The trial will be monitored for safety and efficacy by a Data Safety Monitoring Board (DSMB)
      composed of clinicians, statisticians/methodologists and a lay member appointed by the McGill
      University Health center.

      Adverse events (AEs) are defined as any untoward medical occurrence in a subject which does
      not necessarily have a causal relationship with the study medication/intervention. An AE can
      therefore be any unfavourable and unintended sign (including abnormal laboratory finding),
      symptom, or disease temporally associated with the use of study drug/intervention, whether or
      not it is related to the medication/intervention.

      Stable chronic conditions which are present prior to clinical study entry and do not worsen
      are not considered adverse events and will be accounted for in the subject's medical history.

      Subjects who have an adverse event should be followed and treated by the Investigator until
      the abnormal parameter or symptom has resolved or stabilized. It is up to the clinician to
      determine that the AE is either resolved or that is has reached a stable state, after which
      no further follow-up is necessary. There should also be source documentation to support this
      determination. At each contact with the subject, information regarding adverse events will be
      elicited by appropriate questioning and examinations, and will be recorded immediately on a
      source document (e.g., progress notes, laboratory reports, survey tools, and data collection
      tools). The start date, stop date, severity of each reportable event, and the PI's judgment
      of the AE's relationship to the study, medication/intervention will also be recorded.

      Any AE that occurs between baseline and 30 days following Week 24 (or at the time of early
      discontinuation of the subject from the study for any reason) is to be recorded in the source
      documentation (patient will be called). Surveillance for AEs will end at 30 days following
      Week 24. If an serious adverse event (SAE) is ongoing at the time a subject
      discontinues/completes the trial the SAE will be followed until the Investigator agrees that
      the event is satisfactorily resolved or that no further follow-up is required.

      Virologic failure must be considered for any patient with plasma HIV RNA ≥50 c/mL at any time
      following randomization. For the purposes of clinical management in this study, virologic
      failure is defined as: Two consecutive plasma HIV RNA ≥50 c/mL within four weeks of the
      initial suspected virologic failure. Cases of confirmed virologic failure will trigger
      genotypic virologic resistance testing, including integrase resistance testing, when plasma
      HIV RNA >400c/mL. The virologic failure definition is intended for guidance and Investigators
      should use their discretion as to the most appropriate clinical management of their patients.
      Due to the risk of developing integrase resistance in the setting of replicating HIV, change
      of antiretroviral therapy for subjects randomized to raltegravir is indicated for those with
      confirmed virologic failure. The choice of antiretroviral therapy will be left to the
      discretion of the treating physician.

      The conduct of this study will conform to the International Conference for Harmonization and
      Good Clinical Practice (ICH-GCP) regulations and guidelines and the current revision of the
      Declaration of Helsinki A copy of the protocol (including protocol amendments), all versions
      of the informed consents, other information to be completed by subjects such as
      questionnaires, and any proposed advertising/ recruitment materials must be reviewed and
      approved by the research ethics board (REB) of each participating centre prior to
      implementation of the study. The investigator will be responsible for obtaining REB approval
      of the annual Continuing Review throughout the duration of the study. The investigator will
      notify the REB of violations from the protocol and SAEs.

      All subjects will be given detailed oral and written information about the study. Consent
      forms describing in detail the study medications/intervention(s), study procedures,
      anticipated benefits and potential risks will be given to each participant and written
      documentation of informed consent is required prior to starting the study. Subjects must
      voluntarily sign and date an informed consent document that has been approved by the REB
      prior to any procedures being done specifically for the trial. Each subject should have
      sufficient opportunity to discuss the study and consider the information in the consent
      process prior to agreeing to participate. Subjects may withdraw consent at any time during
      the course of the trial. The informed consent will be signed and dated by the subject, the
      person who conducted the informed consent discussion and the investigator. The original
      signed informed consent form will be retained in the subject's study files and a copy will be
      provided to the subject.

      All subject related information including the case report forms (CRFs), laboratory samples,
      evaluation forms, reports, etc. will be kept strictly confidential. All records will be kept
      in a secure, locked location and only research staff will have access to the records.
      Subjects will be identified only by means of a coded number specific to each subject, and a
      subject letter code. All computerized databases will identify subjects by numeric codes only,
      and will be password protected. Upon request, clinical information may be reviewed by or
      released to study monitors, auditors, Canadian Institutes of Health Research or regulatory
      agencies. The REB or other government organizations, as part of their duties to ensure that
      research subjects are protected may discontinue the study at any time. Regulatory authorities
      and the study Sponsor retain the authority to suspend additional enrollment for the entire
      study as applicable.

      Data and study documents at all sites will be stored securely for 25 years, after which they
      will be destroyed in keeping with the privacy and confidentiality regulations and guidelines.

      Appropriate medical and research records for this study and regulatory/ institutional
      requirements must be maintained for the protection of confidentiality of study subjects. The
      Principal Investigator is responsible for assuring that the data collected are complete,
      accurate, and recorded in a timely manner.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Screening
masking: None (Open Label)
measure: improvement of fatty liver or liver fibrosis
time frame: 24 months
description: Difference in Fibroscan/CAP measurement from baseline to 24 months
measure: Difference in serum CK-18 levels
time frame: 24 months
description: Difference in serum CK-18 levels as surrogate diagnostic marker of NASH from baseline to 24 months.
measure: Difference in transaminases levels
time frame: 24 months
description: Difference in transaminases levels (AST and/or ALT) from baseline to 24 months
measure: Difference in metabolic markers
time frame: 24 months
description: Difference in metabolic markers (HOMA; cholesterol or triglycerides levels; BMI) from baseline to 24 months.
arm group label: switch to Isentress
arm group type: Experimental
description: 28 subjects will be prescribed Raltegravir at the standard dose of 400 mg p.o. b.i.d. for 24 months.
arm group label: Continue usual antiretroviral therapy
arm group type: Active Comparator
description: 28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
intervention type: Drug
intervention name: Isentress.
description: 28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
arm group label: switch to Isentress
other name: Raltegravir
intervention type: Other
intervention name: Continue usual antiretroviral therapy
description: 28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
arm group label: Continue usual antiretroviral therapy
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Giada Sebastiani, MD
role: Principal Investigator
affiliation: McGill University Health Centre/Research Institute of the McGill University Health Centre
facility: 
country: Canada
responsible party type: Principal Investigator
investigator affiliation: McGill University Health Centre/Research Institute of the McGill University Health Centre
investigator full name: Giada Sebastiani
investigator title: Dr Giada Sebastiani MD
mesh term: Fatty Liver
mesh term: Non-alcoholic Fatty Liver Disease
mesh term: Raltegravir Potassium
mesh term: Anti-Retroviral Agents